You are here

  • Home
  • Archive
  • Volume 81, Issue 9
  • Correspondence on: ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al

Article Text

Article menu
Download PDFPDF
Correspondence
Correspondence on: ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’ by Pouletty et al
  1. Rosa Pino1,
  2. Ana Carolina Izurieta1,
  3. María Ríos-Barnés2,
  4. Sílvia Ricart1,3,
  5. Mariona F De Sevilla1,4,
  6. Laura Monfort1,
  7. Cristian Launes1,4,
  8. Iván Cano1,
  9. Laura Lecina1,
  10. Judith Sánchez Manubens5,6,
  11. Juan Manuel Mosquera5,
  12. Iolanda Jordan4,7,
  13. Joan Sánchez de Toledo8,9,
  14. Manuel Monsonís10,
  15. Cristina Esteva4,11,
  16. Carmen Muñoz-Almagro4,11,
  17. Victòria Fumadó2,3,
  18. Clàudia Fortuny2,4,
  19. Juan José Garcia Garcia2,4,
  20. Antoni Noguera-Julian2,4,
  21. Jordi Anton3,5
  22. On behalf of the Kids Corona Project
  1. 1 Hospital Medicine Unit, Pediatrics Department, Hospital Sant Joan de Déu, Barcelona, Spain
  2. 2 Infectious Diseases and Systemic Inflammatory Response in Pediatrics, Infectious Diseases Unit, Hospital Sant Joan de Déu, Barcelona, Spain
  3. 3 Faculty of Medicine, Universitat de Barcelona, Barcelona, Spain
  4. 4 CIBERESP, Madrid, Spain
  5. 5 Pediatric Rheumatology Unit, Hospital Sant Joan de Déu, Barcelona, Spain
  6. 6 Pediatric Rheumatology, Consorcio Corporación Sanitaria Parc Taulí, Sabadell, Barcelona, Spain
  7. 7 Pediatric Intensive Care Department, Hospital Sant Joan de Déu, Barcelona, Spain
  8. 8 Pediatric Cardiology Department, Hospital Sant Joan de Déu, Barcelona, Spain
  9. 9 Department of Critical Care Medicine, Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, USA
  10. 10 Department of Microbiology, Hospital Sant Joan de Déu, Barcelona, Spain
  11. 11 Department of Molecular Microbiology, Hospital Sant Joan de Déu, Barcelona, Spain
  1. Correspondence to Professor Antoni Noguera-Julian, Hospital Sant Joan de Déu, Passeig Sant Joan de Déu 2, 08950 Esplugues, Barcelona, Spain; ton{at}sjdhospitalbarcelona.org

https://doi.org/10.1136/annrheumdis-2020-218538

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    We read with interest the article by Pouletty et al,1 in which the authors describe a multicentre compilation of patients with Kawasaki disease (KD) in France, associated with the detection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Other colleagues in Europe and USA have recently reported similar experiences.2–5

    We report a prospective case series of paediatric patients that fulfilled clinical diagnostic criteria of KD during the SARS-CoV-2 pandemic in a paediatric referral centre in Barcelona, Spain. KD was defined according to the 2017 criteria of the American Heart Association.6 Assessment of SARS-CoV-2 infection was made by means of quantitative real-time PCR assay (GeneFinder COVID-19 Plus, Elitech; Puteaux, France) in nasopharyngeal samples; stools were tested in patients with diarrhoea. SARS-CoV-2 IgG qualitative determination (SARS-CoV-2 IgG chemiluminescent microparticle immunoassay; Abbot, Chicago, Illinois) was performed during admission. Statistical analyses were performed using SPSS V.25 (IBM). Informed consent was obtained from parents or legal guardians, as was informed assent in patients aged >12 years.

    From March 23 to May 14, twelve previously healthy patients with KD were admitted to our institution (table 1). The yearly number of patients with KD diagnosed in our centre is around 10–12. Prior to diagnosis, several patients reported gastrointestinal symptoms (10/12, 83.3%; vomiting, diarrhoea and abdominal pain) and neurological symptoms (5/12, 41.6%; irritability, headache, decreased consciousness and febrile seizures). Only patient 10 was referred with respiratory …

    View Full Text

    Footnotes

    • AN-J and JA contributed equally.

    • Contributors RP, IJ, VF, CF, JJGG, ANJ and JA designed the study. RP, ACI, MRB, SR, MFDS, LM, CL, IC, LL, JSM, JMM, JSdT and VF collected the clinical data. MM, CE and CMA supervised the microbiological studies. RP, ANJ and JA analysed the data and wrote the paper. All authors have reviewed and approved the version submitted for publication.

    • Funding This work was supported by 'Subvencions per a la Intensificació de Facultatius Especialistes' (Departament de Salut de la Generalitat de Catalunya, Programa PERIS 2016-2020) (SLT008/18/00193) to ANJ.

    • Competing interests CF has received funds for speaking at symposia organised on behalf of Gilead Sciences. JA has received grants, personal fees and non-financial support from Sobi; grants and personal fees from Novartis; grants from Roche; grants, personal fees and non-financial support from Pfizer; grants and personal fees from BMS; grants from Lilly; grants from Novimmune; grants and personal fees from Gebro; and grants, personal fees and non-financial support from AbbVie, outside the submitted work.

    • Patient and public involvement Patients and/or the public were not involved in the design, or conduct, or reporting, or dissemination plans of this research.

    • Provenance and peer review Not commissioned; internally peer reviewed.

    Linked Articles